Climacteric · 2011 · 59 citations · 20 references
MedicineOncologyPharmacologyEndocrine OncologyEndocrine PharmacotherapyReproductive EndocrinologyBreast Cancer PharmacotherapyHormonal Cancer TherapyHormonal EvaluationHormonal TherapyMenopause PharmacotherapyVaginal Dosage FormsAromatase InhibitionAromatase InhibitorsEndocrine TherapeuticsEstradiol LevelsMenopausal Symptom ReliefSerum Follicle-stimulating HormoneSerum Luteinizing HormoneVaginal Dryness
OBJECTIVE: Aromatase inhibitors are essential as endocrine treatment for hormone receptor-positive postmenopausal breast cancer patients. Menopausal symptoms are often aggravated during endocrine treatment. We investigated whether vaginal estriol is a safe therapeutic option to overcome the urogenital side-effects of aromatase inhibitors. Serum hormone levels were used as the surrogate parameter for safety. METHODS: Fasting serum hormone levels of ten postmenopausal breast cancer patients receiving aromatase inhibitors were prospectively measured by electro-chemiluminescence immunoassays and gas chromatography/mass spectrometry before and 2 weeks after daily application of 0.5 mg vaginal estriol (Ovestin® ovula), respectively. RESULTS: Two weeks of daily vaginal estriol treatment did not change serum estradiol or estriol levels. However, significant decreases in levels of serum follicle stimulating hormone (p = 0.01) and luteinizing hormone (p = 0.02) were observed. Five out of six breast cancer patients noticed an improvement in vaginal dryness and/or dyspareunia. CONCLUSIONS: The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor.
20
Predictors of Sexual Health in Women After a Breast Cancer Diagnosis
Patricia A. Ganz, Katherine A. Desmond, Thomas R. Belin et al. · Journal of Clinical Oncology · 1999 · 355 citations
Medicine, Oncology, Breast Oncology +15